Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28935825 | 0.69 | CYP11B1 (0.54) | ALDH1A1P2RX7CYP11B1CYP11B2QPCT | |
| SCHEMBL12963592 | 0.66 | MTNR1B (0.39) | ALDH1A1LMNAHTT | |
| SCHEMBL7606025 | 0.63 | KDM4E (0.35) | ACHEKDM4ELMNAMAPK1SMN1; SMN2 | |
| SCHEMBL28179114 | 0.62 | CYP11B1 (0.56) | P2RX7CYP11B1CYP11B2 | |
| SCHEMBL6496747 | 0.60 | CYP11B1 (0.63) | P2RX7CYP11B1CYP11B2QPCT | |
| SCHEMBL16892166 | 0.58 | CYP11B1 (0.60) | P2RX7CYP11B1CYP11B2 | |
| SCHEMBL30107166 | 0.58 | CYP11B1 (0.51) | KDM4ECYP11B1CYP11B2 | |
| SCHEMBL20519343 | 0.58 | CYP11B1 (0.51) | KDM4ECYP11B1CYP11B2 | |
| SCHEMBL17544771 | 0.58 | CYP11B1 (0.51) | CYP11B1CYP11B2 | |
| SCHEMBL19907466 | 0.58 | P2RX7 (0.65) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6479530-B2 | SUBSTITUTED 4(5)-(1-INDANYL,-INDANYLMETHYL, INDANYLMETHYLEN), 4(5)-(1-(1,2,3,4-TETRAHYDRONAPHTHYL, -NAPHTHYLMETHYL AND NAPHTHYLMETHYLEN)IMIDAZOLES; HYPOTENSIVE, ISCHEMIC AND ANXIOLYTIC AGENTS; NERVOUS AND MUSCULAR SYSTEM DISORDERS | ORION CORPORATION (FI) | 2002-11-12 | — | — | US | disclosed |
| US-20020007074-A1 | Imidazole derivatives having affinity for alpha2 receptors | KARJALAINEN ARTO (FI) | 2002-01-17 | — | — | US | disclosed |
| US-6313311-B1 | ADRENERGIC STIMULANTS FOR POTENTIATING ANESTHETICS PRIOR TO SURGERY; HYPOTENSIVE AGENTS, ANALGESICS, ANTIISCHEMIC AGENTS; NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS | ORION CORPORATION (FI) | 2001-11-06 | — | — | US | disclosed |
| EP-0888309-A1 | IMIDAZOLE DERIVATIVES HAVING AFFINITY FOR ALPHA2 RECEPTORS ACTIVITY | ORION CORPORATION (FI) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997012874-A1 | IMIDAZOLE DERIVATIVES HAVING AFFINITY FOR ALPHA2 RECEPTORS ACTIVITY | Orion-Yhtymä Oy (FI) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007074-A1 | Imidazole derivatives having affinity for alpha2 receptors | CHRM1, CHRNA1, CNR1 | ACHE 1379/4885KDM4E 3475/4885USP2 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.